Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

1.

Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis.

Tanaka H, Yang GX, Iwakoshi N, Knechtle SJ, Kawata K, Tsuneyama K, Leung P, Coppel RL, Ansari AA, Joh T, Bowlus C, Gershwin ME.

Clin Exp Immunol. 2013 Dec;174(3):364-71. doi: 10.1111/cei.12193.

2.

Immunological potential of cytotoxic T lymphocyte antigen 4 immunoglobulin in murine autoimmune cholangitis.

Tanaka H, Yang GX, Tomiyama T, Tsuneyama K, Zhang W, Leung PS, Coppel RL, Joh T, Nadler SG, Ansari AA, Bowlus C, Gershwin ME.

Clin Exp Immunol. 2015 Jun;180(3):371-82. doi: 10.1111/cei.12581.

3.

Deletion of interleukin-6 in mice with the dominant negative form of transforming growth factor beta receptor II improves colitis but exacerbates autoimmune cholangitis.

Zhang W, Tsuda M, Yang GX, Tsuneyama K, Rong G, Ridgway WM, Ansari AA, Flavell RA, Coppel RL, Lian ZX, Gershwin ME.

Hepatology. 2010 Jul;52(1):215-22. doi: 10.1002/hep.23664.

4.

B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice.

Moritoki Y, Lian ZX, Lindor K, Tuscano J, Tsuneyama K, Zhang W, Ueno Y, Dunn R, Kehry M, Coppel RL, Mackay IR, Gershwin ME.

Hepatology. 2009 Dec;50(6):1893-903. doi: 10.1002/hep.23238. Erratum in: Hepatology. 2010 Jan;51(1):358.

5.

Adoptive transfer of CD8(+) T cells from transforming growth factor beta receptor type II (dominant negative form) induces autoimmune cholangitis in mice.

Yang GX, Lian ZX, Chuang YH, Moritoki Y, Lan RY, Wakabayashi K, Ansari AA, Flavell RA, Ridgway WM, Coppel RL, Tsuneyama K, Mackay IR, Gershwin ME.

Hepatology. 2008 Jun;47(6):1974-82. doi: 10.1002/hep.22226.

6.

The multi-hit hypothesis of primary biliary cirrhosis: polyinosinic-polycytidylic acid (poly I:C) and murine autoimmune cholangitis.

Ambrosini YM, Yang GX, Zhang W, Tsuda M, Shu S, Tsuneyama K, Leung PS, Ansari AA, Coppel RL, Gershwin ME.

Clin Exp Immunol. 2011 Oct;166(1):110-20. doi: 10.1111/j.1365-2249.2011.04453.x.

7.

Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice.

Yoshida K, Yang GX, Zhang W, Tsuda M, Tsuneyama K, Moritoki Y, Ansari AA, Okazaki K, Lian ZX, Coppel RL, Mackay IR, Gershwin ME.

Hepatology. 2009 Nov;50(5):1494-500. doi: 10.1002/hep.23132.

8.

Successful treatment of murine autoimmune cholangitis by parabiosis: Implications for hematopoietic therapy.

Yang JB, Wang YH, Yang W, Lu FT, Ma HD, Zhao ZB, Jia YJ, Tang W, Tsuneyama K, Ridgway WM, Gershwin ME, Lian ZX.

J Autoimmun. 2016 Jan;66:108-17. doi: 10.1016/j.jaut.2015.09.002. Epub 2015 Oct 1.

9.

Identification of potential cytokine pathways for therapeutic intervention in murine primary biliary cirrhosis.

Kawata K, Tsuda M, Yang GX, Zhang W, Tanaka H, Tsuneyama K, Leung P, He XS, Knechtle S, Ansari AA, Coppel RL, Gershwin ME.

PLoS One. 2013 Sep 10;8(9):e74225. doi: 10.1371/journal.pone.0074225. eCollection 2013.

10.

Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice.

Oertelt S, Lian ZX, Cheng CM, Chuang YH, Padgett KA, He XS, Ridgway WM, Ansari AA, Coppel RL, Li MO, Flavell RA, Kronenberg M, Mackay IR, Gershwin ME.

J Immunol. 2006 Aug 1;177(3):1655-60.

11.

Antimitochondrial antibody-negative chronic nonsuppurative destructive cholangitis. Atypical primary biliary cirrhosis or autoimmune cholangitis?

Sánchez-Pobre P, Castellano G, Colina F, Dominguez P, Rodriguez S, Canga F, Herruzo JA.

J Clin Gastroenterol. 1996 Oct;23(3):191-8.

PMID:
8899500
12.

Murine autoimmune cholangitis requires two hits: cytotoxic KLRG1(+) CD8 effector cells and defective T regulatory cells.

Huang W, Kachapati K, Adams D, Wu Y, Leung PS, Yang GX, Zhang W, Ansari AA, Flavell RA, Gershwin ME, Ridgway WM.

J Autoimmun. 2014 May;50:123-34. doi: 10.1016/j.jaut.2014.01.034. Epub 2014 Feb 18.

13.
14.

Disruption of CD40/CD40-ligand interactions in a retinal autoimmunity model results in protection without tolerance.

Bagenstose LM, Agarwal RK, Silver PB, Harlan DM, Hoffmann SC, Kampen RL, Chan CC, Caspi RR.

J Immunol. 2005 Jul 1;175(1):124-30.

15.

Innate immunity drives xenobiotic-induced murine autoimmune cholangitis.

Chang CH, Chen YC, Yu YH, Tao MH, Leung PS, Ansari AA, Gershwin ME, Chuang YH.

Clin Exp Immunol. 2014 Aug;177(2):373-80. doi: 10.1111/cei.12298.

16.

Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse.

Komura K, Fujimoto M, Yanaba K, Matsushita T, Matsushita Y, Horikawa M, Ogawa F, Shimizu K, Hasegawa M, Takehara K, Sato S.

Ann Rheum Dis. 2008 Jun;67(6):867-72. Epub 2007 Sep 6.

PMID:
17823201
17.

Successful immunotherapy of autoimmune cholangitis by adoptive transfer of forkhead box protein 3(+) regulatory T cells.

Tanaka H, Zhang W, Yang GX, Ando Y, Tomiyama T, Tsuneyama K, Leung P, Coppel RL, Ansari AA, Lian ZX, Ridgway WM, Joh T, Gershwin ME.

Clin Exp Immunol. 2014 Nov;178(2):253-61. doi: 10.1111/cei.12415.

18.

Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges.

Law CL, Grewal IS.

Adv Exp Med Biol. 2009;647:8-36. doi: 10.1007/978-0-387-89520-8_2. Review.

PMID:
19760064
19.

Escherichia coli infection induces autoimmune cholangitis and anti-mitochondrial antibodies in non-obese diabetic (NOD).B6 (Idd10/Idd18) mice.

Wang JJ, Yang GX, Zhang WC, Lu L, Tsuneyama K, Kronenberg M, Véla JL, Lopez-Hoyos M, He XS, Ridgway WM, Leung PS, Gershwin ME.

Clin Exp Immunol. 2014 Feb;175(2):192-201. doi: 10.1111/cei.12224.

20.

Innate immunity and primary biliary cirrhosis: activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis.

Wu SJ, Yang YH, Tsuneyama K, Leung PS, Illarionov P, Gershwin ME, Chuang YH.

Hepatology. 2011 Mar;53(3):915-25. doi: 10.1002/hep.24113.

Supplemental Content

Support Center